EAN 2026 Satellite Session

EAN 2026 SATELLITE SESSION Geneva, Switzerland | 28th June 2026

Learn from two leading neurology experts, Prof. Sean J. Pittock (USA) & Prof. Diego Centonze (ITA), from the European Academy of Neurology (EAN) 2026 Satellite Symposium, about the evolution of NMOSD treatments and the latest evidence of complement component 5 inhibitors in adult patients with anti-aquaporin-4 antibody-positive (AQP4-Ab+) NMOSD.

Symposium Objectives:

Understand the burden of unmet needs in adult patients with AQP4-Ab+ NMOSD
Review the evolution of NMOSD treatments
Discuss effectiveness and safety highlights from real-world evidence with ravulizumab and eculizumab

Chairperson
Mayo Clinic
Rochester, MN, United States

Prof. Sean J. Pittock

Sean J. Pittock, M.D., is the Marilyn A. Park and Moon S. Park, M.D., Director of Mayo Clinic's Center for Multiple Sclerosis and Autoimmune Neurology and the principal investigator of Mayo's Neuroimmunology Research Laboratory.

Prof. Pittock's clinical and laboratory expertise lies in modifying, for clinical application, the antibody assays developed by the Neuroimmunology Research Laboratory. Specific areas of focus include multidisciplinary, collaborative research into autoimmune neurological disorders, autoimmune gastrointestinal dysmotility (AGID) and neuromyelitis optica spectrum disorder (NMOSD).
Complementing his laboratory research, Prof. Pittock is the founder of the Autoimmune Neurology Clinic in the Center for Multiple Sclerosis and Autoimmune Neurology, which interacts closely with the Neuroimmunology Research Laboratory and has allowed the development of a unique translational practice extending the laboratory's serological findings directly to the bedside. This new, 21st-century subspecialty addresses diagnosis and treatment of organ-specific autoimmune disorders that target the central and peripheral nervous systems.

Tor Vergata University
Rome, Italy

Prof. Diego Centonze

Diego Centonze, MD, PhD is a Full Professor of Neurology at the Department of Systems Medicine of the University of Rome Tor Vergata and Director of the Neurology Unit and the Neurorehabilitation Unit at the Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mediterranean Neurological Institute Neuromed. He is also Head of the Laboratory of Synaptic Immunopathology of the University of Rome Tor Vergata. His main interest in clinical research is the evaluation of new drugs for the treatment of multiple sclerosis. His research activity is aimed at investigating the role of synaptic transmission and plasiticity in the pathophysiology of multiple sclerosis and its experimental model and the mechanisms of neurodegenerative damage in neurological diseases, such as neuromyelitis optica spectrum disorder (NMOSD). Prof. Centonze graduated in Medicine from the University of Rome La Sapienza in 1994 and obtained a specialization in Neurology at the University of Rome Tor Vergata in 1999, a specialization in Psychiatry in 2006 and a PhD in Advanced Technology in Rehabilitation Medicine in 2012.

Prof. Centonze participates, as Principal Investigator, in numerous national and international phase II, III and IV clinical trials for the experimental treatment of Multiple Sclerosis and NMOSD and also serves as a member of multiple international Advisory Boards for the optimization of the pharmacological treatment of Multiple Sclerosis. He is a member of the Society for Neuroscience (SFN), the Italian Neurological Society (SIN), the Italian Society for Neuroscience (SINS), the Steering Committee of AINI (Italian Association of Neuroimmunology), the Medical Academy of Rome, the Steering Committee of ECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis) and the IPMSC (International Progressive Multiple Sclerosis Collaborative Initiative). He is the author of over 500 scientific papers on neurology, neurophysiology, neuroscience and psychiatry published in international peer-reviewed and indexed journals.

This company-sponsored symposium at the EAN 2026 was organised and funded by Alexion, AstraZeneca Rare Disease and intended for Healthcare Professionals. This presentation includes data relating to eculizumab and ravulizumab.

SOLIRIS^® (eculizumab) is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody-positive with a relapsing course of the disease.

ULTOMIRIS^® (ravulizumab) is indicated in the treatment of adult patients with NMOSD who are anti-aquaporin 4 (AQP4) antibody-positive.

Eculizumab EU Summary of Product Characteristics

Ravulizumab EU Summary of Product Characteristics

Prescribing information may differ from country to country. Please refer to your locally approved label and take this into consideration when viewing this information.

Please verify reimbursement status applicable in your country.

SAFETY INFORMATION

Please report any adverse reactions via your national reporting system. Adverse events can also be reported to Alexion pharmaceuticals by the following email:

I am a healthcare professional registered in the UK & EU

I am not a
healthcare professional